Department of Anesthesia, Hyogo Rehabilitation Centre Central Hospital, Kobe, Hyogo 651-2181 Japan.
Division of Anesthesia, Nishiwaki Municipal Hospital, 652-1 Shimotoda, Nishiwaki, Hyogo 677-0043 Japan ; Department of Emergency and Critical Care Medicine, Kobe University Hospital, Kobe, Hyogo 650-0017 Japan.
J Intensive Care. 2015 Nov 14;3:49. doi: 10.1186/s40560-015-0115-2. eCollection 2015.
Sepsis is a potentially fatal syndrome mediated by an early [e.g., tumor necrosis factor-alpha (TNF-α)] and late [high mobility group box-1 (HMGB-1)] proinflammatory cytokine response to infection. Sepsis-induced acute kidney injury (AKI) is associated with a high mortality. C-Fos/activator protein-1 (AP-1) controls the transactivation of proinflammatory cytokines via AP-1 binding in the promoter region. T-5224 is a de novo small molecule inhibitor of c-Fos/AP-1 that controls gene expression of multiple proinflammatory cytokines. We investigated whether T-5224, a selective inhibitor of c-Fos/AP-1, improves survival in lethal lipopolysaccharide (LPS)-induced AKI by inhibiting early (TNF-α) and late (HMGB-1) proinflammatory cytokine response.
Mice were divided into four groups (control, LPS, LPS + T-5224, and T-5224 only). Control mice were administered polyvinylpyrrolidone (PVP) solution orally, immediately after intraperitoneal (i.p.) saline injection. LPS mice were administered PVP solution orally immediately after i.p. LPS (10 mg/kg) injection. LPS + T-5224 mice were administered T-5224 orally (300 mg/kg) immediately after i.p. LPS injection. T-5224 mice were administered T-5224 orally (300 mg/kg) after i.p. saline injection. Serum concentrations of TNF-α, HMBG-1, and interleukin (IL)-10 were measured by enzyme-linked immunosorbent assay (ELISA). Serum blood urea nitrogen (BUN) and creatinine concentrations were commercially analyzed. Finally, histological examination was performed on the kidney.
Treatment with T-5224 decreased serum TNF-α and HMGB-1 levels and increased survival after LPS injection. Furthermore, T-5224 treatment decreased serum BUN and creatinine concentrations but increased serum IL-10 concentration. LPS-induced pathological changes in kidney were attenuated by T-5224 treatment.
These results suggest that T-5224, a selective inhibitor of c-Fos/AP-1, inhibits expression of early and late proinflammatory cytokines, protecting mice from LPS-induced lethality. T-5224 is a potential approach for decreasing lethality in sepsis-induced AKI.
脓毒症是一种潜在致命的综合征,由感染引起的早期[例如肿瘤坏死因子-α(TNF-α)]和晚期[高迁移率族蛋白-1(HMGB-1)]促炎细胞因子反应介导。脓毒症引起的急性肾损伤(AKI)与高死亡率相关。c-Fos/激活蛋白-1(AP-1)通过 AP-1 在启动子区域的结合来控制促炎细胞因子的转录激活。T-5224 是一种新的 c-Fos/AP-1 的小分子抑制剂,可控制多种促炎细胞因子的基因表达。我们研究了选择性 c-Fos/AP-1 抑制剂 T-5224 是否通过抑制早期(TNF-α)和晚期(HMGB-1)促炎细胞因子反应来改善致死性脂多糖(LPS)诱导的 AKI 中的存活率。
将小鼠分为四组(对照组、LPS 组、LPS+T-5224 组和 T-5224 组)。对照组小鼠在腹腔(i.p.)生理盐水注射后立即口服聚乙烯吡咯烷酮(PVP)溶液。LPS 组小鼠在 i.p. LPS(10mg/kg)注射后立即口服 PVP 溶液。LPS+T-5224 组小鼠在 i.p. LPS 注射后立即口服 T-5224(300mg/kg)。T-5224 组小鼠在 i.p. 生理盐水注射后口服 T-5224(300mg/kg)。通过酶联免疫吸附试验(ELISA)测量血清 TNF-α、HMBG-1 和白细胞介素(IL)-10 的浓度。血清血尿素氮(BUN)和肌酐浓度采用商业方法分析。最后,对肾脏进行组织学检查。
T-5224 治疗可降低 LPS 注射后血清 TNF-α和 HMGB-1 水平并提高存活率。此外,T-5224 治疗可降低血清 BUN 和肌酐浓度,但增加血清 IL-10 浓度。T-5224 治疗可减轻 LPS 诱导的肾脏病理变化。
这些结果表明,c-Fos/AP-1 的选择性抑制剂 T-5224 抑制早期和晚期促炎细胞因子的表达,可保护小鼠免受 LPS 诱导的致死性。T-5224 是降低脓毒症诱导的 AKI 致死率的一种有潜力的方法。